At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of generalized social phobia per DSM-IV criteria
- ✓Able to provide written informed consent
- ✓English-speaking
- ✕Prior or current schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, or antisocial/schizotypal/schizoid personality disorders
- ✕Suicidal thoughts
- ✕History of failed paroxetine treatment (≥6 weeks at adequate doses) or failed prior adequate CBT trial
- ✕Clinically significant or unstable medical disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CBT Augmentation of Paroxetine for Social Anxiety
In Brief
A Phase 3 clinical trial evaluating Paroxetine and Cognitive behavioral therapy (CBT) for Social Anxiety Disorder. Completed, enrolled 150 participants across 2 sites.
Detailed Summary
This study will examine whether the addition of cognitive behavioral therapy can improve the efficacy of the medication paroxetine (Paxil®) in treating individuals with social anxiety disorder. Patients with social anxiety disorder will undergo a 12-week open trial with paroxetine. Those who complete the open trial having achieved only partial response will be randomized to receive cognitive behavioral therapy (CBT) in addition to paroxetine or to continue on paroxetine alone for an additional 16 weeks.
Study Details
Timeline
Interventions
Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
CBT will consist of 16 weekly treatment sessions.